Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 248 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Adult Male Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose AME Study With [14C]AR882 in Healthy Male Subjects

NCT04508426
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]AR882
Drug
Lead sponsor
Arthrosi Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Losartan and PA21

NCT01324752
View directory record Official record
Conditions
Drug Interaction Potentiation
Interventions
PA21 and Losartan with Food, No PA21; Losartan with food, PA21 with food and Losartan 2 hours later
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
20 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open Label Trial of Nissle 1917

NCT02276508
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
E. coli Nissle 1917
Drug
Lead sponsor
Elizabeth Lucas
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

NCT05797753
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Healthy Volunteer
Interventions
SAR443820, Erythromycin ethyl succinate, Itraconazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

NCT06562985
View directory record Official record
Conditions
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
Interventions
BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw

NCT01646060
View directory record Official record
Conditions
Blood Loss, Healthy
Interventions
CM-1500
Device
Lead sponsor
Zynex Monitoring Solutions
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Reduction in Pain Intensity Following IV or Oral Pain-relieving Products

NCT02678416
View directory record Official record
Conditions
Pain
Interventions
IV Acetaminophen (Treatment A), Oral Acetaminophen (Treatment B), Placebo (Treatment C), Morphine (Treatment D)
Drug · Other
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetic, Safety, Tolerability and Relative Bioavailability of Gepotidacin in Healthy Adult Male and Female Participants

NCT05271799
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

NCT06554639
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
MK-5684, Prednisone, Fludrocortisone acetate, Diltiazem hydrocholoride
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

NCT01299805
View directory record Official record
Conditions
Healthy
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

NCT05955872
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis (FSGS)
Interventions
VX-147
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of Lesinurad and Intravenous [14C]Lesinurad

NCT02039700
View directory record Official record
Conditions
Healthy
Interventions
Lesinurad 400 mg, [14C]lesinurad (100 μg per 10 mL)
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 8, 2026, 2:47 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of JPH034 in Healthy Adult Participants

NCT07534657
View directory record Official record
Conditions
Health Adult Subjects
Interventions
JPH034, Placebo Control
Drug · Other
Lead sponsor
J-Pharma Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

NCT04650542
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
HBI-3000, Paroxetine
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

NCT01776437
View directory record Official record
Conditions
Human Volunteers
Interventions
BMN 673
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects

NCT01232413
View directory record Official record
Conditions
Healthy Subjects, Cardiac Repolarization
Interventions
Placebo, ASP1941, Moxifloxacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

NCT04828265
View directory record Official record
Conditions
Healthy Male
Interventions
Aldafermin
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 8, 2026, 2:47 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

NCT03275740
View directory record Official record
Conditions
Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

NCT07171619
View directory record Official record
Conditions
Healthy
Interventions
Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

NCT06301971
View directory record Official record
Conditions
Healthy Participants
Interventions
Emraclidine
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants

NCT05963932
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986419 DR Capsule, BMS-986419 IR Tablet
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

NCT01915212
View directory record Official record
Conditions
Healthy Volunteers
Interventions
HSV529, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Omeprazole and PA21

NCT01452906
View directory record Official record
Conditions
Healthy
Interventions
PA21 and Omeprazole with food, No PA21; Omeprazole with food, PA21 with food, Omeprazole 2hrs later
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
20 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Oct 8, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose

NCT06908954
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Palovarotene
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 8, 2026, 2:47 PM EDT